相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Activation of WEE1 confers resistance to PI3K inhibition in glioblastoma
Shaofang Wu et al.
NEURO-ONCOLOGY (2018)
Phase 0 Trial of AZD1775 in First-Recurrence Glioblastoma Patients
Nader Sanai et al.
CLINICAL CANCER RESEARCH (2018)
Adult Brainstem Gliomas With H3K27M Mutation: Radiology, Pathology, and Prognosis
Elena V. Daoud et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2018)
Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers
Janeta Popovici-Muller et al.
ACS MEDICINAL CHEMISTRY LETTERS (2018)
GAPVAC-101: First-in-human trial of a highly personalized peptide vaccination approach for patients with newly diagnosed glioblastoma
Wolfgang Wick et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Phase II study of pembrolizumab or pembrolizumab plus bevacizumab for recurrent glioblastoma (rGBM) patients
David A. Reardon et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Phase 2 trial of SL-701 in relapsed/refractory (r/r) glioblastoma (GBM): Correlation of immune response with longer-term survival.
David M. Peereboom et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer
Yi-Long Wu et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive Glioblastoma
Sara A. Byron et al.
CLINICAL CANCER RESEARCH (2018)
Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma
Jayashree Kalpathy-Cramer et al.
JOURNAL OF NEURO-ONCOLOGY (2017)
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial
Michael Weller et al.
LANCET ONCOLOGY (2017)
Phase II trial of dacomitinib, a pan-human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification
Juan Manuel Sepulveda-Sanchez et al.
NEURO-ONCOLOGY (2017)
Recurrent glioma clinical trial, CheckMate-143: the game is not over yet
Anna C. Filley et al.
ONCOTARGET (2017)
ONC201: a new treatment option being tested clinically for recurrent glioblastoma
Marie D. Ralff et al.
TRANSLATIONAL CANCER RESEARCH (2017)
Phase 2 study to evaluate safety and efficacy of MEDI4736 (durvalumab [DUR]) in glioblastoma (GBM) patients: An update.
David A. Reardon et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2-Amplified and TP53 Wild-type Glioblastomas
Maite Verreault et al.
CLINICAL CANCER RESEARCH (2016)
A Cancer Research UK First Time in Human Phase I Trial of IMA950 (Novel Multipeptide Therapeutic Vaccine) in Patients with Newly Diagnosed Glioblastoma
Roy Rampling et al.
CLINICAL CANCER RESEARCH (2016)
Phase I trial of dovitinib (TKI258) in recurrent glioblastoma
Niklas Schaefer et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2016)
Superselective intraarterial cerebral infusion of cetuximab after osmotic blood/brain barrier disruption for recurrent malignant glioma: phase I study
Shamik Chakraborty et al.
JOURNAL OF NEURO-ONCOLOGY (2016)
Wilms tumor 1 peptide vaccination combined with temozolomide against newly diagnosed glioblastoma: safety and impact on immunological response
Naoya Hashimoto et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2015)
Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors
Josep Tabernero et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Dendritic cell-based immunotherapy targeting Wilms' tumor 1 in patients with recurrent malignant glioma
Keiichi Sakai et al.
JOURNAL OF NEUROSURGERY (2015)
The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents
Jude Canon et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Structural and functional features of central nervous system lymphatic vessels
Antoine Louveau et al.
NATURE (2015)
Phase II study of PX-866 in recurrent glioblastoma
Marshall W. Pitz et al.
NEURO-ONCOLOGY (2015)
Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627)
Andrew B. Lassman et al.
NEURO-ONCOLOGY (2015)
A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study
James Schuster et al.
NEURO-ONCOLOGY (2015)
Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma
Patrick Y. Wen et al.
NEURO-ONCOLOGY (2015)
Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer (vol 368, pg 2385, 2013)
[Anonymous]
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
David M. Hyman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Stephen M. Ansell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Single cell-derived clonal analysis of human glioblastoma links functional and genomic heterogeneity
Mona Meyer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas
Andrew D. Norden et al.
JOURNAL OF NEURO-ONCOLOGY (2015)
Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma
David A. Reardon et al.
NEURO-ONCOLOGY (2015)
A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K
Daniel J. Ma et al.
NEURO-ONCOLOGY (2015)
WT1 expression increases with malignancy and indicates unfavourable outcome in astrocytoma
Julian Rauscher et al.
JOURNAL OF CLINICAL PATHOLOGY (2014)
A vaccine targeting mutant IDH1 induces antitumour immunity
Theresa Schumacher et al.
NATURE (2014)
Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02
Patrick Y. Wen et al.
NEURO-ONCOLOGY (2014)
Bevacizumab for Newly Diagnosed Glioblastoma Reply
Olivier L. Chinot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Bevacizumab plus Radiotherapy-Temozolomide for Newly Diagnosed Glioblastoma
Olivier L. Chinot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma
Surasak Phuphanich et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
The Somatic Genomic Landscape of Glioblastoma
Cameron W. Brennan et al.
CELL (2013)
Phase II Study of Bevacizumab in Combination with Sorafenib in Recurrent Glioblastoma (N0776): A North Central Cancer Treatment Group Trial
Evanthia Galanis et al.
CLINICAL CANCER RESEARCH (2013)
IDH1 and IDH2 Mutations in Gliomas
Adam L. Cohen et al.
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS (2013)
The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma
Brittany C. Parker et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma
Tracy T. Batchelor et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Phase II open-label study of nintedanib in patients with recurrent glioblastoma multiforme
Aida Muhic et al.
JOURNAL OF NEURO-ONCOLOGY (2013)
Salvage therapy with BRAF inhibitors for recurrent pleomorphic xanthoastrocytoma: a retrospective case series
Marc C. Chamberlain
JOURNAL OF NEURO-ONCOLOGY (2013)
CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2006-2010
Quinn T. Ostrom et al.
NEURO-ONCOLOGY (2013)
Human Glioblastoma Multiforme: p53 Reactivation by a Novel MDM2 Inhibitor
Barbara Costa et al.
PLOS ONE (2013)
Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics
Andrea Sottoriva et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
A phase I/II trial of vandetanib for patients with recurrent malignant glioma
Teri N. Kreisl et al.
NEURO-ONCOLOGY (2012)
Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02
Eudocia Q. Lee et al.
NEURO-ONCOLOGY (2012)
Acquired MET expression confers resistance to EGFR inhibition in a mouse model of glioblastoma multiforme
H. J. Jun et al.
ONCOGENE (2012)
Transforming Fusions of FGFR and TACC Genes in Human Glioblastoma
Devendra Singh et al.
SCIENCE (2012)
Differential Sensitivity of Glioma-versus Lung Cancer-Specific EGFR Mutations to EGFR Kinase Inhibitors
Igor Vivanco et al.
CANCER DISCOVERY (2012)
Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma
David A. Reardon et al.
JOURNAL OF NEURO-ONCOLOGY (2011)
Phase II study of sunitinib malate in patients with recurrent high-grade glioma
B. Neyns et al.
JOURNAL OF NEURO-ONCOLOGY (2011)
Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide
Elizabeth R. Gerstner et al.
JOURNAL OF NEURO-ONCOLOGY (2011)
Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib-A Phase II Trial
Monika E. Hegi et al.
MOLECULAR CANCER THERAPEUTICS (2011)
BRAF V600E Mutations Are Common in Pleomorphic Xanthoastrocytoma: Diagnostic and Therapeutic Implications
Dora Dias-Santagata et al.
PLOS ONE (2011)
Concurrent Radiotherapy and Temozolomide Followed by Temozolomide and Sorafenib in the First-Line Treatment of Patients With Glioblastoma Multiforme
John D. Hainsworth et al.
CANCER (2010)
Pharmacologic Inhibition of Cyclin-Dependent Kinases 4 and 6 Arrests the Growth of Glioblastoma Multiforme Intracranial Xenografts
Karine Michaud et al.
CANCER RESEARCH (2010)
Vaccine provides new hope for patients with deadly brain cancer
[Anonymous]
FUTURE NEUROLOGY (2010)
Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma
David A. Reardon et al.
JOURNAL OF NEURO-ONCOLOGY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma
John H. Sampson et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma
B. Neyns et al.
ANNALS OF ONCOLOGY (2009)
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Henry S. Friedman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034
Martin J. van den Bent et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma
Teri N. Kreisl et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors
Joannes F. M. Jacobs et al.
NEURO-ONCOLOGY (2009)
IDH1 and IDH2 Mutations in Gliomas
Hai Yan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme
Shuichi Izumoto et al.
JOURNAL OF NEUROSURGERY (2008)
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
L. Chin et al.
NATURE (2008)
Gefitinib in patients with progressive high-grade gliomas:: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)
E. Franceschi et al.
BRITISH JOURNAL OF CANCER (2007)
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma
Andrew T. Parsa et al.
NATURE MEDICINE (2007)
Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: Tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01
AB Lassman et al.
CLINICAL CANCER RESEARCH (2005)
Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme
SM Chang et al.
INVESTIGATIONAL NEW DRUGS (2005)
B7-homolog I expression by human glioma: a new mechanism of immune evasion
R Wilmotte et al.
NEUROREPORT (2005)
Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis
B Kaur et al.
NEURO-ONCOLOGY (2005)
PI3K/Akt/mTOR pathway as a target for cancer therapy
D Morgensztern et al.
ANTI-CANCER DRUGS (2005)
Phase II trial of gefitinib in recurrent glioblastoma
JN Rich et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Three or more routes for leukocyte migration into the central nervous system
RM Ransohoff et al.
NATURE REVIEWS IMMUNOLOGY (2003)
Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma:: Biological and clinical results
FF Lang et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
SG O'Brien et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Receptor tyrosine kinase signalling as a target for cancer intervention strategies
E Zwick et al.
ENDOCRINE-RELATED CANCER (2001)
Wilms' tumor gene (WT1) expression in lung cancer, colon cancer and glioblastoma cell lines compared to freshly isolated tumor specimens
HD Menssen et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2000)
分享论文
